UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s Why

UCB SA (OTCMKTS:UCBJF) gapped down before the market opened on Wednesday. The stock had previously closed at $328.91, but opened at $314.48. UCB shares last traded at $314.48, with a volume of 27 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on UCBJF shares. Stephens reaffirmed an “overweight” rating on shares of UCB in a research note on Wednesday, October 21st. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Finally, Jefferies Financial Group raised shares of UCB to a “hold” rating in a research report on Monday, August 3rd. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

UCB Stock Down 4.4%

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The stock’s 50-day simple moving average is $265.27 and its two-hundred day simple moving average is $286.45.

About UCB

UCB is a Belgian biopharmaceutical company founded in 1928 and headquartered in Brussels. It discovers, develops and commercializes medicines, with a focus on neurological and immunological conditions. Its products include treatments for epilepsy, such as Keppra, Briviact and Nayzilam, as well as medicines for inflammatory diseases, including Cimzia and Bimzelx. UCB also develops therapies for other serious conditions, including myasthenia gravis. The company serves patients and healthcare providers in markets around the world.